Published in Cancer Weekly, July 4th, 2000
This Phase I grant, entitled "Antibodies to New Amplified Breast Cancer Gene Products," supports research to create antibodies to novel amplified breast cancer gene products that will be used for immunochemical assays.
Tularik uses Representational Difference Analysis (RDA), a proprietary technique, in combination with other technology to discover cancer genes (oncogenes) that are amplified at the DNA level. The ultimate goal of this project...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.